National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Abemaciclib (Verzenios®) for adjuvant HR positive, HER2 negative, node positive early breast cancer. HTA ID: 22020

Abemaciclib in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence.


NCPE Assessment Process Complete
Rapid review commissioned 11/04/2022
Rapid review completed 06/05/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/05/2022
Pre-submission consultation with Applicant 26/07/2022
Current Status Awaiting HTA submission from Applicant